Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

Hims & Hers Health, Inc.’s HIMS investors are reaping some gains from the stock of late. Shares of the San Francisco, ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 ...

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health HIMS. And retail traders should know ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) reached a new 52-week high on Monday after TD Cowen raised their price target on the stock from $25.00 to $28.00. TD Cowen currently ...